{"id":"vorinostat","rwe":[{"pmid":"41903478","year":"2026","title":"Design, synthesis, and in silico study of VEGFR-2 and HDAC dual acting quinazoline based molecules for anticancer evaluation.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"},{"pmid":"41895167","year":"2026","title":"In silico discovery of selective TPX2 and BUB1B inhibitors as novel antimitotic agents in breast cancer therapy.","finding":"","journal":"Computational biology and chemistry","studyType":"Clinical Study"},{"pmid":"41885112","year":"2026","title":"Latent HIV Reservoirs in the Central Nervous System: Mechanisms, Barriers, and Therapeutic Approaches.","finding":"","journal":"ACS infectious diseases","studyType":"Clinical Study"},{"pmid":"41880788","year":"2026","title":"Towards the discovery of potent epigenetic modulators: Design, synthesis, biological evaluation, and SAR investigation of novel indole-based derivatives targeting HDAC1 and HDAC6.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"},{"pmid":"41878673","year":"2026","title":"Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"}],"_fda":{"id":"27d99e44-bbc6-445d-b08b-e32fd8702dc3","set_id":"cd86ee78-2781-468b-930c-3c4677bcc092","openfda":{"nui":["N0000175588","N0000175071"],"upc":["0300060568404"],"unii":["58IFB293JI"],"route":["ORAL"],"rxcui":["668579","668606"],"spl_id":["27d99e44-bbc6-445d-b08b-e32fd8702dc3"],"brand_name":["ZOLINZA"],"spl_set_id":["cd86ee78-2781-468b-930c-3c4677bcc092"],"package_ndc":["0006-0568-40"],"product_ndc":["0006-0568"],"generic_name":["VORINOSTAT"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["VORINOSTAT"],"pharm_class_epc":["Histone Deacetylase Inhibitor [EPC]"],"pharm_class_moa":["Histone Deacetylase Inhibitors [MoA]"],"manufacturer_name":["Merck Sharp & Dohme LLC"],"application_number":["NDA021991"],"is_original_packager":[true]},"version":"27","pregnancy":["8.1 Pregnancy Risk Summary Based on its mechanism of action and findings from animal studies, ZOLINZA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are insufficient data on ZOLINZA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, administration of vorinostat to pregnant rats and rabbits during the period of organogenesis caused adverse developmental outcomes at maternal exposures approximately 0.5 times the human exposure based on AUC 0-24 hours (see Data ) . Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Results of animal studies indicate that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Doses up to 50 and 150 mg/kg/day were tested in rats and rabbits, respectively (~0.5 times the human exposure based on AUC 0-24 hours ). Treatment-related developmental effects including decreased mean live fetal weights, incomplete ossifications of the skull, thoracic vertebra, sternebra, and skeletal variations (cervical ribs, supernumerary ribs, vertebral count and sacral arch variations) were seen in rats at the highest dose of vorinostat tested. Reductions in mean live fetal weight and an elevated incidence of incomplete ossification of the metacarpals were seen in rabbits dosed at 150 mg/kg/day. The no observed effect levels (NOELs) for these findings were 15 and 50 mg/kg/day (<0.1 times the human exposure based on AUC) in rats and rabbits, respectively. A dose-related increase in the incidence of malformations of the gall bladder was noted in all drug treatment groups in rabbits versus the concurrent control."],"overdosage":["10 OVERDOSAGE No specific information is available on the treatment of overdosage of ZOLINZA. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required. It is not known if vorinostat is dialyzable."],"references":["15 REFERENCES 1. \"OSHA Hazardous Drugs.\" OSHA. [ http://www.osha.gov/SLTC/hazardousdrugs/index.html ]"],"description":["11 DESCRIPTION ZOLINZA contains vorinostat, which is described chemically as N- hydroxy- N'- phenyloctanediamide. The empirical formula is C 14 H 20 N 2 O 3 . The molecular weight is 264.32 and the structural formula is: Vorinostat is a white to light orange powder. It is very slightly soluble in water, slightly soluble in ethanol, isopropanol and acetone, freely soluble in dimethyl sulfoxide and insoluble in methylene chloride. It has no chiral centers and is non-hygroscopic. The differential scanning calorimetry ranged from 161.7 (endotherm) to 163.9°C. The pH of saturated water solutions of vorinostat drug substance was 6.6. The pKa of vorinostat was determined to be 9.2. Each 100 mg ZOLINZA capsule for oral administration contains 100 mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate. The capsule shell excipients are titanium dioxide, gelatin and sodium lauryl sulfate. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING ZOLINZA capsules, 100 mg, are white, opaque hard gelatin capsules with \"568\" over \"100 mg\" printed within the radial bar in black ink on the capsule body. They are supplied as follows: NDC 0006-0568-40. Each bottle contains 120 capsules. Storage and Handling Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. ZOLINZA (vorinostat) capsules should not be opened or crushed. Direct contact of the powder in ZOLINZA capsules with the skin or mucous membranes should be avoided. If such contact occurs, wash thoroughly as outlined in the references. Personnel should avoid exposure to crushed and/or broken capsules [see Nonclinical Toxicology (13.1) ]."],"geriatric_use":["8.5 Geriatric Use Clinical studies of ZOLINZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ZOLINZA in pediatric patients have not been established."],"effective_time":"20241112","clinical_studies":["14 CLINICAL STUDIES Cutaneous T-cell Lymphoma In two open-label clinical studies, patients with refractory CTCL have been evaluated to determine their response rate to oral ZOLINZA. One study was a single-arm clinical study and the other assessed several dosing regimens. In both studies, patients were treated until disease progression or intolerable toxicity. Study 1 In an open-label, single-arm, multicenter non-randomized study (NCT00091559), 74 patients with advanced CTCL were treated with ZOLINZA at a dose of 400 mg once daily. The primary endpoint was response rate to oral ZOLINZA in the treatment of skin disease in patients with advanced CTCL (Stage IIB and higher) who had progressive, persistent, or recurrent disease on or following two systemic therapies. Enrolled patients should have received, been intolerant to or not a candidate for bexarotene. Extent of skin disease was quantitatively assessed by investigators using a modified Severity Weighted Assessment Tool (SWAT). The investigator measured the percentage total body surface area (%TBSA) involvement separately for patches, plaques, and tumors within 12 body regions using the patient's palm as a \"ruler\". The total %TBSA for each lesion type was multiplied by a severity weighting factor (1=patch, 2=plaque and 4=tumor) and summed to derive the SWAT score. Efficacy was measured as either a Complete Clinical Response (CCR) defined as no evidence of disease, or Partial Response (PR) defined as a ≥50% decrease in SWAT skin assessment score compared to baseline. Both CCR and PR had to be maintained for at least 4 weeks. Secondary efficacy endpoints included response duration, time to progression, and time to objective response. The population had been exposed to a median of three prior therapies (range 1 to 12). Table 2 summarizes the demographic and disease characteristics of the Study 1 population. Table 2: Baseline Patient Characteristics (All Patients As Treated) Characteristics Vorinostat (N=74) Age (year) Mean (SD) 61.2 (11.3) Median (Range) 60.0 (39.0, 83.0) Gender, n (%) Male 38 (51.4%) Female 36 (48.6%) CTCL stage, n (%) IB 11 (14.9%) IIA 2 (2.7%) IIB 19 (25.7%) III 22 (29.7%) IVA 16 (21.6%) IVB 4 (5.4%) Racial Origin, n (%) Asian 1 (1.4%) Black 11 (14.9%) Other 1 (1.4%) White 61 (82.4%) Time from Initial CTCL Diagnosis (year) Median (Range) 2.6 (0.0, 27.3) Clinical Characteristics Number of prior systemic treatments, median (range) 3.0 (1.0, 12.0) The overall objective response rate was 29.7% (22/74, 95% CI [19.7 to 41.5%]) in all patients treated with ZOLINZA. In patients with Stage IIB and higher CTCL, the overall objective response rate was 29.5% (18/61). One patient with Stage IIB CTCL achieved a CCR. Median times to response were 55 and 56 days (range 28 to 171 days), respectively in the overall population and in patients with Stage IIB and higher CTCL. However, in rare cases it took up to 6 months for patients to achieve an objective response to ZOLINZA. The median response duration was not reached since the majority of responses continued at the time of analysis, but was estimated to exceed 6 months for both the overall population and in patients with Stage IIB and higher CTCL. When end of response was defined as a 50% increase in SWAT score from the nadir, the estimated median response duration was 168 days and the median time to tumor progression was 202 days. Using a 25% increase in SWAT score from the nadir as criterion for tumor progression, the estimated median time-to-progression was 148 days for the overall population and 169 days in the 61 patients with Stage IIB and higher CTCL. Response to any previous systemic therapy does not appear to be predictive of response to ZOLINZA. Study 2 In an open-label, non-randomized study, ZOLINZA was evaluated to determine the response rate for patients with CTCL who were refractory or intolerant to at least one treatment. In this study, 33 patients were assigned to one of 3 cohorts: Cohort 1, 400 mg once daily; Cohort 2, 300 mg twice daily 3 days/week; or Cohort 3, 300 mg twice daily for 14 days followed by a 7-day rest (induction). In Cohort 3, if at least a partial response was not observed then patients were dosed with a maintenance regimen of 200 mg twice daily. The primary efficacy endpoint, objective response, was measured by the 7-point Physician's Global Assessment (PGA) scale. The investigator assessed improvement or worsening in overall disease compared to baseline based on overall clinical impression. Index and non-index cutaneous lesions as well as cutaneous tumors, lymph nodes and all other disease manifestations were also assessed and included in the overall clinical impression. CCR required 100% clearing of all findings, and PR required at least 50% improvement in disease findings. The median age was 67.0 years (range 26.0 to 82.0). Fifty-five percent of patients were male, and 45% of patients were female. Fifteen percent of patients had Stage IA, IB, or IIA CTCL and 85% of patients had Stage IIB, III, IVA, or IVB CTCL. The median number of prior systemic therapies was 4 (range 0.0 to 11.0). In all patients treated, the objective response was 24.2% (8/33) in the overall population, 25% (7/28) in patients with Stage IIB or higher disease and 36.4% (4/11) in patients with Sezary syndrome. The overall response rates were 30.8%, 9.1% and 33.3% in Cohort 1, Cohort 2 and Cohort 3, respectively. The 300 mg twice daily regimen had higher toxicity with no additional clinical benefit over the 400 mg once daily regimen. No CCR was observed. Among the 8 patients who responded to study treatment, the median time to response was 83.5 days (range 25 to 153 days). The median response duration was 106 days (range 66 to 136 days). Median time to progression was 211.5 days (range 94 to 255 days)."],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology A randomized, partially-blind, placebo-controlled, 2-period crossover study was performed to assess the effects of a single 800-mg dose of vorinostat on the QTc interval in 24 patients with advanced cancer. This study was conducted to assess the impact of vorinostat on ventricular repolarization. The upper bound of the 90% confidence interval of the placebo-adjusted mean QTc interval change-from-baseline was less than 10 msec at every time point through 24 hours. Based on these study results, administration of a single supratherapeutic 800-mg dose of vorinostat does not appear to prolong the QTc interval in patients with advanced cancer; however the study did not include a positive control to demonstrate assay sensitivity. In the fasted state, oral administration of a single 800-mg dose of vorinostat resulted in a mean AUC and C max and median T max of 8.6±5.7 µM∙hr and 1.7±0.67 µM and 2.1 (0.5-6) hours, respectively. In clinical studies in patients with CTCL, three of 86 CTCL patients exposed to 400 mg once daily had Grade 1 (>450-470 msec) or 2 (>470-500 msec or increase of >60 msec above baseline) clinical adverse reactions of QTc prolongation. In a retrospective analysis of three Phase 1 and two Phase 2 studies, 116 patients had a baseline and at least one follow-up ECG. Four patients had Grade 2 (>470-500 msec or increase of >60 msec above baseline) and 1 patient had Grade 3 (>500 msec) QTc prolongation. In 49 non-CTCL patients from 3 clinical trials who had complete evaluation of QT interval, 2 had QTc measurements of >500 msec and 1 had a QTc prolongation of >60 msec."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption The pharmacokinetics of vorinostat were evaluated in 23 patients with relapsed or refractory advanced cancer. After oral administration of a single 400-mg dose of vorinostat with a high-fat meal, the mean ± standard deviation area under the curve (AUC) and peak serum concentration (C max ) and the median (range) time to maximum concentration (T max ) were 5.5±1.8 µM∙hr, 1.2±0.62 µM and 4 (2-10) hours, respectively. In the fasted state, oral administration of a single 400-mg dose of vorinostat resulted in a mean AUC and C max and median T max of 4.2±1.9 µM∙hr and 1.2±0.35 µM and 1.5 (0.5-10) hours, respectively. Therefore, oral administration of vorinostat with a high-fat meal resulted in an increase (33%) in the extent of absorption and a modest decrease in the rate of absorption (T max delayed 2.5 hours) compared to the fasted state. However, these small effects are not expected to be clinically meaningful. In clinical trials of patients with CTCL, vorinostat was taken with food. At steady state in the fed-state, oral administration of multiple 400-mg doses of vorinostat resulted in a mean AUC and C max and a median T max of 6.0±2.0 µM∙hr, 1.2±0.53 µM and 4 (0.5-14) hours, respectively. Distribution Vorinostat is approximately 71% bound to human plasma proteins over the range of concentrations of 0.5 to 50 µg/mL. Metabolism The major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by β-oxidation. Human serum levels of two metabolites, O -glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O -glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP). Excretion Vorinostat is eliminated predominantly through metabolism with less than 1% of the dose recovered as unchanged drug in urine, indicating that renal excretion does not play a role in the elimination of vorinostat. The mean urinary recovery of two pharmacologically inactive metabolites at steady state was 16±5.8% of vorinostat dose as the O -glucuronide of vorinostat, and 36±8.6% of vorinostat dose as 4-anilino-4-oxobutanoic acid. Total urinary recovery of vorinostat and these two metabolites averaged 52±13.3% of vorinostat dose. The mean terminal half-life (t ½ ) was ~2.0 hours for both vorinostat and the O -glucuronide metabolite, while that of the 4-anilino-4-oxobutanoic acid metabolite was 11 hours. Specific Populations Gender, Race & Age Based upon an exploratory analysis of limited data, gender, race and age do not appear to have meaningful effects on the pharmacokinetics of vorinostat. Pediatric Vorinostat was not evaluated in patients <18 years of age. Hepatic Impairment The single dose pharmacokinetics of a 400 mg ZOLINZA dose was evaluated in patients with non-CTCL cancers with varying degrees of hepatic impairment. The mean AUC of vorinostat in patients with mild (bilirubin > 1 to 1.5 × ULN or AST > ULN but bilirubin ≤ ULN) and moderate (bilirubin 1.5 to ≤ 3 × ULN) hepatic impairment increased by 50% compared to the AUC of vorinostat in patients with normal hepatic function. The mean vorinostat AUC in patients with severe hepatic impairment (bilirubin > 3 × ULN) increased by 66% compared to the AUC of patients with normal hepatic function. The safety of multiple daily doses of ZOLINZA was also evaluated in patients with non-CTCL cancers with varying degrees of hepatic impairment. The highest dose studied in mild, moderate and severe hepatic impairment was 400, 300 and 200 mg daily respectively. The incidence of Grade 3 or 4 adverse reactions was similar among the hepatic function groups. The most common Grade 3 or 4 adverse reaction was thrombocytopenia. Reduce the dose in patients with mild to moderate hepatic impairment. There is not enough data in patients with severe hepatic impairment to recommend a dose modification [see Dosage and Administration (2.2) and Use in Specific Populations (8.6) ]. Renal Insufficiency Vorinostat was not evaluated in patients with renal impairment. However, renal excretion does not play a role in the elimination of vorinostat. Pharmacokinetic Effects of Vorinostat with Other Agents Vorinostat is not an inhibitor of CYP drug metabolizing enzymes in human liver microsomes at steady state C max of the 400 mg dose (C max of 1.2 µM vs IC 50 of >75 µM). Gene expression studies in human hepatocytes detected some potential for suppression of CYP2C9 and CYP3A4 activities by vorinostat at concentrations higher (≥10 µM) than pharmacologically relevant. Thus, vorinostat is not expected to affect the pharmacokinetics of other agents. As vorinostat is not eliminated via the CYP pathways, it is anticipated that vorinostat will not be subject to drug-drug interactions when co-administered with drugs that are known CYP inhibitors or inducers. However, no formal clinical studies have been conducted to evaluate drug interactions with vorinostat. In vitro studies indicate that vorinostat is not a substrate of human P-glycoprotein (P-gp). In addition, vorinostat has no inhibitory effect on human P-gp-mediated transport of vinblastine (a marker P-gp substrate) at concentrations of up to 100 µM. Thus, vorinostat is not likely to inhibit P-gp at the pharmacologically relevant serum concentration of 2 µM (C max ) in humans."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions have been associated with ZOLINZA in clinical trials and are discussed in greater detail in other sections of the label: Thromboembolism [see Warnings and Precautions (5.1) ] Myelosuppression [see Warnings and Precautions (5.2) ] Gastrointestinal Toxicity [see Warnings and Precautions (5.3) ] Hyperglycemia [see Warnings and Precautions (5.4) ] Clinical Chemistry Abnormalities [see Warnings and Precautions (5.5) ] Severe thrombocytopenia when combined with other Histone Deacetylase (HDAC) Inhibitors [see Warnings and Precautions (5.6) ] The most common adverse reactions (incidence ≥20%) are diarrhea, fatigue, nausea, thrombocytopenia, anorexia and dysgeusia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ZOLINZA was evaluated in 107 CTCL patients in two single arm clinical studies in which 86 patients received 400 mg once daily. The data described below reflect exposure to ZOLINZA 400 mg once daily in the 86 patients for a median number of 97.5 days on therapy (range 2 to 480+ days). Seventeen (19.8%) patients were exposed beyond 24 weeks and 8 (9.3%) patients were exposed beyond 1 year. The population of CTCL patients studied was 37 to 83 years of age, 47.7% female, 52.3% male, and 81.4% white, 16.3% black, and 1.2% Asian or multi-racial. Common Adverse Reactions The most common drug-related adverse reactions can be classified into 4 symptom complexes: gastrointestinal symptoms (diarrhea, nausea, anorexia, weight decrease, vomiting, constipation), constitutional symptoms (fatigue, chills), hematologic abnormalities (thrombocytopenia, anemia), and taste disorders (dysgeusia, dry mouth). The most common serious drug-related adverse reactions were pulmonary embolism and anemia. Table 1 summarizes the frequency of CTCL patients with specific adverse reactions, using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 3.0). Table 1: Clinical or Laboratory Adverse Reactions Occurring in CTCL Patients (Incidence ≥10% of patients) ZOLINZA 400 mg once daily (N=86) Adverse Reactions All Grades Grades 3-4 n % n % Fatigue 45 52.3 3 3.5 Diarrhea 45 52.3 0 0.0 Nausea 35 40.7 3 3.5 Dysgeusia 24 27.9 0 0.0 Thrombocytopenia 22 25.6 5 5.8 Anorexia 21 24.4 2 2.3 Weight Decreased 18 20.9 1 1.2 Muscle Spasms 17 19.8 2 2.3 Alopecia 16 18.6 0 0.0 Dry Mouth 14 16.3 0 0.0 Blood Creatinine Increased 14 16.3 0 0.0 Chills 14 16.3 1 1.2 Vomiting 13 15.1 1 1.2 Constipation 13 15.1 0 0.0 Dizziness 13 15.1 1 1.2 Anemia 12 14.0 2 2.3 Decreased Appetite 12 14.0 1 1.2 Peripheral Edema 11 12.8 0 0.0 Headache 10 11.6 0 0.0 Pruritus 10 11.6 1 1.2 Cough 9 10.5 0 0.0 Upper Respiratory Infection 9 10.5 0 0.0 Pyrexia 9 10.5 1 1.2 The frequencies of more severe thrombocytopenia, anemia [see Warnings and Precautions (5.2) ] and fatigue were increased at doses higher than 400 mg once daily of ZOLINZA. Serious Adverse Reactions The most common serious adverse reactions in the 86 CTCL patients in two clinical trials were pulmonary embolism reported in 4.7% (4/86) of patients, squamous cell carcinoma reported in 3.5% (3/86) of patients and anemia reported in 2.3% (2/86) of patients. There were single events of cholecystitis, death (of unknown cause), deep vein thrombosis, enterococcal infection, exfoliative dermatitis, gastrointestinal hemorrhage, infection, lobar pneumonia, myocardial infarction, ischemic stroke, pelviureteric obstruction, sepsis, spinal cord injury, streptococcal bacteremia, syncope, T-cell lymphoma, thrombocytopenia and ureteric obstruction. Discontinuations Of the CTCL patients who received the 400-mg once daily dose, 9.3% (8/86) of patients discontinued ZOLINZA due to adverse reactions. These adverse reactions, regardless of causality, included anemia, angioneurotic edema, asthenia, chest pain, exfoliative dermatitis, death, deep vein thrombosis, ischemic stroke, lethargy, pulmonary embolism, and spinal cord injury. Dose Modifications Of the CTCL patients who received the 400-mg once daily dose, 10.5% (9/86) of patients required a dose modification of ZOLINZA due to adverse reactions. These adverse reactions included increased serum creatinine, decreased appetite, hypokalemia, leukopenia, nausea, neutropenia, thrombocytopenia and vomiting. The median time to the first adverse reactions resulting in dose reduction was 42 days (range 17 to 263 days). Laboratory Abnormalities Laboratory abnormalities were reported in all of the 86 CTCL patients who received the 400-mg once-daily dose. Increased serum glucose was reported as a laboratory abnormality in 69% (59/86) of CTCL patients who received the 400-mg once daily dose; only 4 of these abnormalities were severe (Grade 3). Increased serum glucose was reported as an adverse reaction in 8.1% (7/86) of CTCL patients who received the 400-mg once daily dose [see Warnings and Precautions (5.4) ]. Transient increases in serum creatinine were detected in 46.5% (40/86) of CTCL patients who received the 400-mg once daily dose. Of these laboratory abnormalities, 34 were NCI CTCAE Grade 1, 5 were Grade 2, and 1 was Grade 3. Proteinuria was detected as a laboratory abnormality (51.4%) in 38 of 74 patients tested. The clinical significance of this finding is unknown. Dehydration Based on reports of dehydration as a serious drug-related adverse reaction in clinical trials, patients were instructed to drink at least 2 L/day of fluids for adequate hydration [see Warnings and Precautions (5.3 , 5.5) ]. Adverse Reactions in Non-CTCL Patients The frequencies of individual adverse reactions were substantially higher in the non-CTCL population. Drug-related serious adverse reactions reported in the non-CTCL population which were not observed in the CTCL population included single events of blurred vision, asthenia, hyponatremia, tumor hemorrhage, Guillain-Barré syndrome, renal failure, urinary retention, cough, hemoptysis, hypertension, and vasculitis. In patients recovering from bowel surgery and treated perioperatively with ZOLINZA, anastomotic healing complications including fistulas, perforations, and abscess formation have occurred."],"contraindications":["4 CONTRAINDICATIONS None. None ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Coumarin-derivative anticoagulants: Prolongation of prothrombin time and International Normalized Ratio (INR) have been observed with concomitant use. Monitor INR frequently. ( 7.1 ) 7.1 Coumarin-Derivative Anticoagulants Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. Physicians should monitor PT and INR more frequently in patients concurrently administered ZOLINZA and coumarin derivatives. 7.2 Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). Monitor platelet count every 2 weeks for the first 2 months [see Warnings and Precautions (5.6) ]."],"mechanism_of_action":["12.1 Mechanism of Action Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC 50 <86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene transcription. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro , vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized."],"storage_and_handling":["Storage and Handling Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. ZOLINZA (vorinostat) capsules should not be opened or crushed. Direct contact of the powder in ZOLINZA capsules with the skin or mucous membranes should be avoided. If such contact occurs, wash thoroughly as outlined in the references. Personnel should avoid exposure to crushed and/or broken capsules [see Nonclinical Toxicology (13.1) ]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC 50 <86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene transcription. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro , vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. 12.2 Pharmacodynamics Cardiac Electrophysiology A randomized, partially-blind, placebo-controlled, 2-period crossover study was performed to assess the effects of a single 800-mg dose of vorinostat on the QTc interval in 24 patients with advanced cancer. This study was conducted to assess the impact of vorinostat on ventricular repolarization. The upper bound of the 90% confidence interval of the placebo-adjusted mean QTc interval change-from-baseline was less than 10 msec at every time point through 24 hours. Based on these study results, administration of a single supratherapeutic 800-mg dose of vorinostat does not appear to prolong the QTc interval in patients with advanced cancer; however the study did not include a positive control to demonstrate assay sensitivity. In the fasted state, oral administration of a single 800-mg dose of vorinostat resulted in a mean AUC and C max and median T max of 8.6±5.7 µM∙hr and 1.7±0.67 µM and 2.1 (0.5-6) hours, respectively. In clinical studies in patients with CTCL, three of 86 CTCL patients exposed to 400 mg once daily had Grade 1 (>450-470 msec) or 2 (>470-500 msec or increase of >60 msec above baseline) clinical adverse reactions of QTc prolongation. In a retrospective analysis of three Phase 1 and two Phase 2 studies, 116 patients had a baseline and at least one follow-up ECG. Four patients had Grade 2 (>470-500 msec or increase of >60 msec above baseline) and 1 patient had Grade 3 (>500 msec) QTc prolongation. In 49 non-CTCL patients from 3 clinical trials who had complete evaluation of QT interval, 2 had QTc measurements of >500 msec and 1 had a QTc prolongation of >60 msec. 12.3 Pharmacokinetics Absorption The pharmacokinetics of vorinostat were evaluated in 23 patients with relapsed or refractory advanced cancer. After oral administration of a single 400-mg dose of vorinostat with a high-fat meal, the mean ± standard deviation area under the curve (AUC) and peak serum concentration (C max ) and the median (range) time to maximum concentration (T max ) were 5.5±1.8 µM∙hr, 1.2±0.62 µM and 4 (2-10) hours, respectively. In the fasted state, oral administration of a single 400-mg dose of vorinostat resulted in a mean AUC and C max and median T max of 4.2±1.9 µM∙hr and 1.2±0.35 µM and 1.5 (0.5-10) hours, respectively. Therefore, oral administration of vorinostat with a high-fat meal resulted in an increase (33%) in the extent of absorption and a modest decrease in the rate of absorption (T max delayed 2.5 hours) compared to the fasted state. However, these small effects are not expected to be clinically meaningful. In clinical trials of patients with CTCL, vorinostat was taken with food. At steady state in the fed-state, oral administration of multiple 400-mg doses of vorinostat resulted in a mean AUC and C max and a median T max of 6.0±2.0 µM∙hr, 1.2±0.53 µM and 4 (0.5-14) hours, respectively. Distribution Vorinostat is approximately 71% bound to human plasma proteins over the range of concentrations of 0.5 to 50 µg/mL. Metabolism The major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by β-oxidation. Human serum levels of two metabolites, O -glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O -glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP). Excretion Vorinostat is eliminated predominantly through metabolism with less than 1% of the dose recovered as unchanged drug in urine, indicating that renal excretion does not play a role in the elimination of vorinostat. The mean urinary recovery of two pharmacologically inactive metabolites at steady state was 16±5.8% of vorinostat dose as the O -glucuronide of vorinostat, and 36±8.6% of vorinostat dose as 4-anilino-4-oxobutanoic acid. Total urinary recovery of vorinostat and these two metabolites averaged 52±13.3% of vorinostat dose. The mean terminal half-life (t ½ ) was ~2.0 hours for both vorinostat and the O -glucuronide metabolite, while that of the 4-anilino-4-oxobutanoic acid metabolite was 11 hours. Specific Populations Gender, Race & Age Based upon an exploratory analysis of limited data, gender, race and age do not appear to have meaningful effects on the pharmacokinetics of vorinostat. Pediatric Vorinostat was not evaluated in patients <18 years of age. Hepatic Impairment The single dose pharmacokinetics of a 400 mg ZOLINZA dose was evaluated in patients with non-CTCL cancers with varying degrees of hepatic impairment. The mean AUC of vorinostat in patients with mild (bilirubin > 1 to 1.5 × ULN or AST > ULN but bilirubin ≤ ULN) and moderate (bilirubin 1.5 to ≤ 3 × ULN) hepatic impairment increased by 50% compared to the AUC of vorinostat in patients with normal hepatic function. The mean vorinostat AUC in patients with severe hepatic impairment (bilirubin > 3 × ULN) increased by 66% compared to the AUC of patients with normal hepatic function. The safety of multiple daily doses of ZOLINZA was also evaluated in patients with non-CTCL cancers with varying degrees of hepatic impairment. The highest dose studied in mild, moderate and severe hepatic impairment was 400, 300 and 200 mg daily respectively. The incidence of Grade 3 or 4 adverse reactions was similar among the hepatic function groups. The most common Grade 3 or 4 adverse reaction was thrombocytopenia. Reduce the dose in patients with mild to moderate hepatic impairment. There is not enough data in patients with severe hepatic impairment to recommend a dose modification [see Dosage and Administration (2.2) and Use in Specific Populations (8.6) ]. Renal Insufficiency Vorinostat was not evaluated in patients with renal impairment. However, renal excretion does not play a role in the elimination of vorinostat. Pharmacokinetic Effects of Vorinostat with Other Agents Vorinostat is not an inhibitor of CYP drug metabolizing enzymes in human liver microsomes at steady state C max of the 400 mg dose (C max of 1.2 µM vs IC 50 of >75 µM). Gene expression studies in human hepatocytes detected some potential for suppression of CYP2C9 and CYP3A4 activities by vorinostat at concentrations higher (≥10 µM) than pharmacologically relevant. Thus, vorinostat is not expected to affect the pharmacokinetics of other agents. As vorinostat is not eliminated via the CYP pathways, it is anticipated that vorinostat will not be subject to drug-drug interactions when co-administered with drugs that are known CYP inhibitors or inducers. However, no formal clinical studies have been conducted to evaluate drug interactions with vorinostat. In vitro studies indicate that vorinostat is not a substrate of human P-glycoprotein (P-gp). In addition, vorinostat has no inhibitory effect on human P-gp-mediated transport of vinblastine (a marker P-gp substrate) at concentrations of up to 100 µM. Thus, vorinostat is not likely to inhibit P-gp at the pharmacologically relevant serum concentration of 2 µM (C max ) in humans."],"indications_and_usage":["1 INDICATIONS AND USAGE ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Thromboembolism: Monitor for pertinent signs and symptoms of pulmonary embolism and deep vein thrombosis. ( 5.1 ) Myelosuppression: Thrombocytopenia and anemia may require dose modification or discontinuation. Monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter. ( 2.2 , 5.2 , 6 ) Gastrointestinal Toxicity: Nausea, vomiting and diarrhea; patients may require antiemetics, antidiarrheals, and fluid and electrolyte replacement to prevent dehydration. ( 5.3 , 6 ) Hyperglycemia: Monitor blood glucose every 2 weeks during the first 2 months of therapy and monthly thereafter. ( 5.4 ) Clinical Chemistry Abnormalities: Measure and correct abnormal electrolytes, creatinine, magnesium and calcium at baseline. Monitor every 2 weeks during the first 2 months of therapy and at least monthly during treatment. ( 5.5 ) Severe Thrombocytopenia with Concomitant Use of other HDAC Inhibitors: Severe thrombocytopenia with gastrointestinal bleeding has been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). Monitor platelet counts more frequently. ( 5.6 , 7.2 ) Embryo-Fetal Toxicity: Fetal harm can occur when administered to a pregnant woman. Women should be apprised of the potential harm to the fetus. ( 5.7 ) 5.1 Thromboembolism Pulmonary embolism occurred in 5% (4/86) of patients receiving ZOLINZA, and deep vein thrombosis has also been reported. Monitor for signs and symptoms of these events, particularly in patients with a prior history of thromboembolic events [see Adverse Reactions (6) ] . 5.2 Myelosuppression Treatment with ZOLINZA can cause dose-related thrombocytopenia and anemia. Monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter. Adjust dosage or discontinue treatment with ZOLINZA as clinically appropriate [see Dosage and Administration (2.2) , Warnings and Precautions (5.6) and Adverse Reactions (6) ]. 5.3 Gastrointestinal Toxicity Gastrointestinal disturbances, including nausea, vomiting and diarrhea, have been reported [see Adverse Reactions (6) ] and may require the use of antiemetic and antidiarrheal medications. Fluid and electrolytes should be replaced to prevent dehydration [see Adverse Reactions (6.1) ] . Pre-existing nausea, vomiting, and diarrhea should be adequately controlled before beginning therapy with ZOLINZA. 5.4 Hyperglycemia Hyperglycemia has been observed in patients receiving ZOLINZA and was severe in 5% (4/86) of patients [see Adverse Reactions (6.1) ] . Monitor serum glucose every 2 weeks during the first 2 months of therapy and monthly thereafter. 5.5 Clinical Chemistry Abnormalities Obtain chemistry tests, including serum electrolytes, creatinine, magnesium, and calcium, every 2 weeks during the first 2 months of therapy and monthly thereafter. Correct hypokalemia and hypomagnesemia prior to administration of ZOLINZA. Monitor potassium and magnesium more frequently in symptomatic patients (e.g., patients with nausea, vomiting, diarrhea, fluid imbalance or cardiac symptoms). 5.6 Severe Thrombocytopenia when Combined with Other Histone Deacetylase (HDAC) Inhibitors Severe thrombocytopenia leading to gastrointestinal bleeding has been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). Monitor platelet counts more frequently [see Drug Interactions (7.2) ] . 5.7 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, ZOLINZA can cause fetal harm when administered to a pregnant woman. There are insufficient data on ZOLINZA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, vorinostat crossed the placenta and caused adverse developmental outcomes at exposures approximately 0.5 times the human exposure based on AUC 0-24 hours . Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the last dose. Advise males with female sexual partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose [see Use in Specific Populations (8.1 , 8.3) and Clinical Pharmacology (12.1) ] ."],"clinical_studies_table":["
Table 2: Baseline Patient Characteristics (All Patients As Treated)
CharacteristicsVorinostat (N=74)
Age (year)
Mean (SD) 61.2 (11.3)
Median (Range) 60.0 (39.0, 83.0)
Gender, n (%)
Male 38 (51.4%)
Female 36 (48.6%)
CTCL stage, n (%)
IB 11 (14.9%)
IIA 2 (2.7%)
IIB 19 (25.7%)
III 22 (29.7%)
IVA 16 (21.6%)
IVB 4 (5.4%)
Racial Origin, n (%)
Asian 1 (1.4%)
Black 11 (14.9%)
Other 1 (1.4%)
White 61 (82.4%)
Time from Initial CTCL Diagnosis (year)
Median (Range) 2.6 (0.0, 27.3)
Clinical Characteristics
Number of prior systemic treatments, median (range) 3.0 (1.0, 12.0)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with vorinostat. Vorinostat was mutagenic in vitro in the bacterial reverse mutation assays (Ames test), caused chromosomal aberrations in vitro in Chinese hamster ovary (CHO) cells and increased the incidence of micro-nucleated erythrocytes when administered to mice (Mouse Micronucleus Assay). Treatment-related effects on female reproduction were identified in the oral fertility study when females were dosed for 14 days prior to mating through gestational day 7. Doses of 15, 50 and 150 mg/kg/day to rats resulted in approximate exposures of 0.15, 0.36 and 0.70 times the expected clinical exposure based on AUC. Dose-dependent increases in corpora lutea were noted at ≥15 mg/kg/day, which resulted in increased peri-implantation losses at ≥50 mg/kg/day. At 150 mg/kg/day, there were increases in the incidences of dead fetuses and in resorptions. No effects on reproductive performance or fertility were observed in male rats dosed (20, 50, 150 mg/kg/day; approximate exposures of 0.15, 0.36 and 0.70 times the expected clinical exposure based on AUC) for 70 days prior to mating with untreated females."],"adverse_reactions_table":["
Table 1: Clinical or Laboratory Adverse Reactions Occurring in CTCL Patients (Incidence ≥10% of patients)
ZOLINZA 400 mg once daily (N=86)
Adverse ReactionsAll GradesGrades 3-4
n%n%
Fatigue4552.333.5
Diarrhea4552.300.0
Nausea3540.733.5
Dysgeusia2427.900.0
Thrombocytopenia2225.655.8
Anorexia2124.422.3
Weight Decreased1820.911.2
Muscle Spasms1719.822.3
Alopecia1618.600.0
Dry Mouth1416.300.0
Blood Creatinine Increased1416.300.0
Chills1416.311.2
Vomiting1315.111.2
Constipation1315.100.0
Dizziness1315.111.2
Anemia1214.022.3
Decreased Appetite1214.011.2
Peripheral Edema1112.800.0
Headache1011.600.0
Pruritus1011.611.2
Cough910.500.0
Upper Respiratory Infection910.500.0
Pyrexia910.511.2
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Patients should be instructed to drink at least 2 L/day of fluid to prevent dehydration and should promptly report excessive vomiting or diarrhea to their physician. Patients should be instructed about the signs of deep vein thrombosis and should consult their physician should any evidence of deep vein thrombosis develop. Patients receiving ZOLINZA should seek immediate medical attention if unusual bleeding occurs. ZOLINZA capsules should not be opened or crushed. Embryo-Fetal Toxicity Advise patients that ZOLINZA can cause fetal harm when administered during pregnancy [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ] . Contraception Advise females of reproductive potential to use effective contraception during treatment with ZOLINZA and for at least 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception and to avoid fathering a child during treatment with ZOLINZA and for at least 3 months after the last dose [see Use in Specific Populations (8.3) ] . Lactation Advise lactating women not to breastfeed during treatment with ZOLINZA and for at least 1 week after the last dose [see Use in Specific Populations (8.2) ] ."],"spl_unclassified_section":["Manuf. for: Merck Sharp & Dohme LLC Rahway, NJ 07065, USA Manufactured by: Patheon, Inc. Mississauga, Ontario, Canada L5N 7K9 For patent information: www.msd.com/research/patent Copyright © 2006-2022 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. uspi-mk0683-c-2207r010"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION 400 mg orally once daily with food. ( 2.1 ) If patient is intolerant to therapy, reduce the dose to 300 mg orally once daily with food. If necessary, reduce the dose further to 300 mg once daily with food for 5 consecutive days each week. ( 2.2 , 5 ) Reduce dose in patients with mild or moderate hepatic impairment. ( 2.2 ) 2.1 Dosing Information The recommended dose is 400 mg orally once daily with food. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity. ZOLINZA capsules should not be opened or crushed [see How Supplied/Storage and Handling (16) ] . 2.2 Dose Modifications For Toxicity If a patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. The dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week, as necessary. Hepatic Impairment Reduce the starting dose to 300 mg orally once daily with food in patients with mild to moderate hepatic impairment (bilirubin 1 to 3 × ULN or AST greater than ULN). There is insufficient evidence to recommend a starting dose for patients with severe hepatic impairment (bilirubin greater than 3 × ULN) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["ZOLINZA vorinostat VORINOSTAT VORINOSTAT GELATIN, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM SODIUM LAURYL SULFATE TITANIUM DIOXIDE white, opaque 568;100;mg"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Capsules: 100 mg white, opaque, hard gelatin capsules with \"568\" over \"100 mg\" printed within radial bar in black ink on the capsule body. Capsules: 100 mg ( 3 )"],"spl_patient_package_insert":["Patient Information ZOLINZA ® (zo LINZ ah) (vorinostat) capsules What is ZOLINZA? ZOLINZA is a prescription medicine for a type of cancer called cutaneous T-cell lymphoma (CTCL), which is a blood cell cancer that affects your skin. ZOLINZA is used when your CTCL gets worse, does not go away, or comes back after you have taken other medicines. What you need to know about ZOLINZA Before you take this medicine, be sure you understand what it is used for and how to take it safely. Keep this information. If you have questions about this medicine, ask your doctor or pharmacist. Every time you get a refill, look at the Patient Information. There may be new information. It is not known if ZOLINZA is safe and effective in children. Should I take ZOLINZA? Pregnancy ZOLINZA has not been studied in pregnant women. It can hurt your baby while you are pregnant. Women of childbearing potential (women who can become pregnant and bear children) should use contraception while taking ZOLINZA and for up to 6 months after the last dose. Please speak with your doctor. Men who have female partners who can become pregnant and bear children, should use contraception while taking ZOLINZA and for up to 3 months after taking the last dose. Please speak with your doctor. Breastfeeding We do not know if ZOLINZA can pass into breast milk. Women should not breastfeed while using ZOLINZA and for up to 1 week after the last dose. Please speak with your doctor. Diabetes If you are taking ZOLINZA and have high blood sugar (hyperglycemia) or diabetes, your doctor may need to change your diet or diabetes medicine to help control your blood sugar. Check your blood sugar as often as your doctor tells you to. If your blood sugar is higher than normal, call your doctor. If you cannot eat or drink like you usually do because you feel sick, vomit, or have diarrhea, call your doctor. If you have any of these conditions, tell your doctor before taking ZOLINZA: a blood clot in your lung (called a Pulmonary Embolus or PE) a blood clot in a vein or blood vessel (called Deep Vein Thrombosis or DVT) high blood sugar (hyperglycemia) or diabetes liver disease nausea, vomiting or diarrhea any allergies Are you taking other medicines? Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Other medicines can affect the way ZOLINZA works. Your doctor may want to do blood tests more often if you take: valproic acid, a medicine for seizures a blood thinner, like Coumadin ® (warfarin) How do I take ZOLINZA? Take ZOLINZA exactly as prescribed by your doctor. Your doctor will tell you how many capsules to take, and when to take them. Take with food. Drink 8 glasses of water every day (at least 8 ounces each). This will help to keep you hydrated, especially if you have nausea, vomiting or diarrhea. Do not chew or break open the capsule. If you break open or crush a capsule, do not touch the capsule or powder. If the powder gets on your skin or in your eyes, wash your skin or eyes with lots of water right away. Then, call your doctor. If you cannot swallow the capsule, tell your doctor. You may need a different medicine. What if I forget to take ZOLINZA? If you miss a dose, take it as soon as you remember. If you do not remember until it is almost time for your next dose, just skip the missed dose and take the next dose at your regular time. Do not take two doses of ZOLINZA at the same time. If you are not sure what to do, call your doctor. If you take more than your prescribed dose, call your doctor, poison center, or emergency room right away. ZOLINZA may cause serious side effects If you have any of the following signs or symptoms, tell your doctor right away. Signs of a blood clot in your legs- Deep Vein Thrombosis or DVT Your leg swells up or feels warm Your leg hurts or feels very tender Your leg hurts when you stand or walk Your skin turns red or changes color Signs of a blood clot in your lungs- Pulmonary Embolus or PE You have sudden, sharp chest pain You feel short of breath You cough up blood You start sweating Your heart is beating very fast You feel like you might pass out You feel very anxious Signs of losing too much fluid from your body- dehydration You can become dehydrated if you cannot eat or drink like you usually do. This can happen when you feel sick, vomit, or have diarrhea. Call your doctor if you get any of these signs or symptoms: Your mouth is dry You are sleepier than usual Your skin is dry You feel dizzy or lightheaded Changes in your blood Your doctor will check your blood during treatment with ZOLINZA. Here is a list of some side effects that may mean you have a change in your blood: You feel more tired than usual You have bleeding or your skin is bruising easily You have high blood sugar (you may feel more hungry or thirsty, you may urinate more often than usual) You look pale You feel short of breath Common side effects of ZOLINZA Diarrhea Constipation Nausea Vomiting Not hungry Losing weight Dry mouth Losing hair Change in the way things taste Muscle aches Itchy skin Feeling tired Feeling dizzy Swelling in the foot, ankle, and leg Cold Cough Chills Fever Headaches If you have any side effect that bothers you or does not go away, tell your doctor. There may be other side effects to ZOLINZA that are not listed. For information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Where should I keep ZOLINZA? Do not let your medicine get really cold or really hot. Keep it at room temperature. Keep ZOLINZA and all medicines out of the reach of children. More information about ZOLINZA Medicines are sometimes prescribed for purposes other than those listed in the patient information. Do not use ZOLINZA for a condition for which it was not prescribed. Do not give ZOLINZA to other people, even if they have the same condition. It may harm them. This Patient Information summarizes the most important information about ZOLINZA. If you would like more information, talk with your doctor or pharmacist. You can ask them for information about ZOLINZA that was written for healthcare professionals. For more information, call the company that makes ZOLINZA at 1-800-622-4477. What are the ingredients in ZOLINZA? The active ingredient is: vorinostat The inactive ingredients are: microcrystalline cellulose, sodium croscarmellose, magnesium stearate, titanium dioxide, gelatin, and sodium lauryl sulfate. Merck Sharp & Dohme LLC Rahway, NJ 07065, USA Manufactured by: Patheon, Inc., Mississauga, Ontario, Canada L5N 7K9 This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 07/2022 For patent information: www.msd.com/research/patent Copyright © 2006-2022 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. usppi-mk0683-c-2207r009"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on its mechanism of action and findings from animal studies, ZOLINZA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are insufficient data on ZOLINZA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, administration of vorinostat to pregnant rats and rabbits during the period of organogenesis caused adverse developmental outcomes at maternal exposures approximately 0.5 times the human exposure based on AUC 0-24 hours (see Data ) . Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Results of animal studies indicate that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Doses up to 50 and 150 mg/kg/day were tested in rats and rabbits, respectively (~0.5 times the human exposure based on AUC 0-24 hours ). Treatment-related developmental effects including decreased mean live fetal weights, incomplete ossifications of the skull, thoracic vertebra, sternebra, and skeletal variations (cervical ribs, supernumerary ribs, vertebral count and sacral arch variations) were seen in rats at the highest dose of vorinostat tested. Reductions in mean live fetal weight and an elevated incidence of incomplete ossification of the metacarpals were seen in rabbits dosed at 150 mg/kg/day. The no observed effect levels (NOELs) for these findings were 15 and 50 mg/kg/day (<0.1 times the human exposure based on AUC) in rats and rabbits, respectively. A dose-related increase in the incidence of malformations of the gall bladder was noted in all drug treatment groups in rabbits versus the concurrent control. 8.2 Lactation Risk Summary There are no data on the presence of ZOLINZA or its metabolites in human milk, the effects on a breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse drug reactions in a nursing child, advise lactating women not to breastfeed during treatment with ZOLINZA and for at least 1 week after the last dose. 8.3 Females and Males of Reproductive Potential ZOLINZA can cause fetal harm when administered to a pregnant woman [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ] . Pregnancy Testing Perform pregnancy testing in females of reproductive potential within 7 days prior to initiating therapy with ZOLINZA. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with ZOLINZA and for at least 6 months after the last dose. Males Advise males with female partners of reproductive potential to use effective contraception and to avoid fathering a child during treatment with ZOLINZA and for at least 3 months after the last dose. Infertility Based on findings in animals, vorinostat has the potential to affect female fertility [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use The safety and effectiveness of ZOLINZA in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of ZOLINZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. 8.6 Use in Patients with Hepatic Impairment ZOLINZA was studied in 42 patients with non-CTCL cancer and varying degrees of hepatic impairment after single and multiple-dose administration. Compared to patients with normal liver function, AUC increases of 50 to 66% were observed in patients with hepatic impairment. The incidence of Grade 3 or 4 thrombocytopenia increased in patients with mild (bilirubin of 1 to 1.5 × ULN and AST < ULN, or bilirubin ≤ ULN and AST > ULN) and moderate (bilirubin 1.5 to ≤ 3 × ULN) hepatic impairment treated daily at doses of 300 and 200 mg respectively. Patients with severe hepatic impairment (bilirubin > 3 × ULN) have not been treated at doses greater than 200 mg a day. Reduce the initial dose of ZOLINZA in patients with bilirubin 1 to 3 × ULN or AST > ULN [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) ]."],"spl_patient_package_insert_table":["
Patient Information ZOLINZA® (zo LINZ ah) (vorinostat) capsules
","
What is ZOLINZA?
","
What you need to know about ZOLINZABefore you take this medicine, be sure you understand what it is used for and how to take it safely.Keep this information.If you have questions about this medicine, ask your doctor or pharmacist. Every time you get a refill, look at the Patient Information. There may be new information.
","
Should I take ZOLINZA?
","
Are you taking other medicines?
","
How do I take ZOLINZA?
","
What if I forget to take ZOLINZA?
","
ZOLINZA may cause serious side effects
","
Your leg swells up or feels warmYour leg hurts or feels very tenderYour leg hurts when you stand or walkYour skin turns red or changes color
","
You have sudden, sharp chest painYou feel short of breathYou cough up bloodYou start sweatingYour heart is beating very fastYou feel like you might pass outYou feel very anxious
","
Your mouth is dryYou are sleepier than usualYour skin is dryYou feel dizzy or lightheaded
","
You feel more tired than usualYou have bleeding or your skin is bruising easilyYou have high blood sugar (you may feel more hungry or thirsty, you may urinate more often than usual)You look paleYou feel short of breath
","
Common side effects of ZOLINZA
","
DiarrheaConstipationNauseaVomitingNot hungryLosing weightDry mouthLosing hairChange in the way things tasteMuscle achesItchy skinFeeling tiredFeeling dizzySwelling in the foot, ankle, and legColdCoughChillsFeverHeadaches
","
If you have any side effect that bothers you or does not go away, tell your doctor.
","
Where should I keep ZOLINZA?
","
More information about ZOLINZA
","
What are the ingredients in ZOLINZA?
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label NDC 0006-0568-40 Zolinza ® (vorinostat) capsules 100 mg Direct contact of the powder in ZOLINZA capsules with the skin or mucous membranes should be avoided. (See Package Insert.) Rx only 120 Capsules PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with vorinostat. Vorinostat was mutagenic in vitro in the bacterial reverse mutation assays (Ames test), caused chromosomal aberrations in vitro in Chinese hamster ovary (CHO) cells and increased the incidence of micro-nucleated erythrocytes when administered to mice (Mouse Micronucleus Assay). Treatment-related effects on female reproduction were identified in the oral fertility study when females were dosed for 14 days prior to mating through gestational day 7. Doses of 15, 50 and 150 mg/kg/day to rats resulted in approximate exposures of 0.15, 0.36 and 0.70 times the expected clinical exposure based on AUC. Dose-dependent increases in corpora lutea were noted at ≥15 mg/kg/day, which resulted in increased peri-implantation losses at ≥50 mg/kg/day. At 150 mg/kg/day, there were increases in the incidences of dead fetuses and in resorptions. No effects on reproductive performance or fertility were observed in male rats dosed (20, 50, 150 mg/kg/day; approximate exposures of 0.15, 0.36 and 0.70 times the expected clinical exposure based on AUC) for 70 days prior to mating with untreated females."]},"tags":[{"label":"Histone Deacetylase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histone deacetylase 6","category":"target"},{"label":"HDAC6","category":"gene"},{"label":"HDAC1","category":"gene"},{"label":"HDAC2","category":"gene"},{"label":"L01XH01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Primary cutaneous T-cell lymphoma","category":"indication"},{"label":"Msd Sub Merck","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Histone Deacetylase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":242.711,"date":"","count":150,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 150 times (LLR=243)"},{"llr":168.139,"date":"","count":129,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 129 times (LLR=168)"},{"llr":132.721,"date":"","count":113,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=133)"},{"llr":84.833,"date":"","count":39,"signal":"Lymphopenia","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=85)"},{"llr":81.116,"date":"","count":53,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=81)"},{"llr":81.048,"date":"","count":82,"signal":"Dehydration","source":"DrugCentral FAERS","actionTaken":"Reported 82 times (LLR=81)"},{"llr":75.068,"date":"","count":30,"signal":"Torsade de pointes","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=75)"},{"llr":73.153,"date":"","count":104,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 104 times (LLR=73)"},{"llr":65.926,"date":"","count":66,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=66)"},{"llr":64.771,"date":"","count":17,"signal":"Cutaneous T-cell lymphoma","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=65)"},{"llr":62.016,"date":"","count":78,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 78 times (LLR=62)"},{"llr":53.407,"date":"","count":70,"signal":"Sepsis","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=53)"},{"llr":46.203,"date":"","count":26,"signal":"Acute myeloid leukaemia","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=46)"},{"llr":44.776,"date":"","count":16,"signal":"Product administered to patient of inappropriate age","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=45)"},{"llr":44.488,"date":"","count":19,"signal":"Activated partial thromboplastin time prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=44)"}],"drugInteractions":[{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Fatigue","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"25.6%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"20.9%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"20.9%","severity":"serious","_validated":true},{"effect":"Anorexia","drugRate":"20.9%","severity":"serious","_validated":true},{"effect":"Dysgeusia","drugRate":"20.9%","severity":"serious","_validated":true},{"effect":"Pulmonary embolism","drugRate":"4.7%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"4.7%","severity":"serious","_validated":true},{"effect":"Squamous cell carcinoma","drugRate":"3.5%","severity":"serious","_validated":true},{"effect":"Muscle spasms","drugRate":"19.8%","severity":"serious","_validated":true},{"effect":"Alopecia","drugRate":"18.6%","severity":"serious","_validated":true},{"effect":"Dry mouth","drugRate":"16.3%","severity":"serious","_validated":true},{"effect":"Blood creatinine increased","drugRate":"16.3%","severity":"serious","_validated":true},{"effect":"Chills","drugRate":"16.3%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"15.1%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"15.1%","severity":"serious","_validated":true},{"effect":"Dizziness","drugRate":"15.1%","severity":"serious","_validated":true},{"effect":"Decreased appetite","drugRate":"14.0%","severity":"serious","_validated":true},{"effect":"Peripheral edema","drugRate":"12.8%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"11.6%","severity":"serious","_validated":true},{"effect":"Pruritus","drugRate":"11.6%","severity":"serious","_validated":true},{"effect":"Cough","drugRate":"10.5%","severity":"serious","_validated":true},{"effect":"Upper respiratory infection","drugRate":"10.5%","severity":"serious","_validated":true},{"effect":"Pyrexia","drugRate":"10.5%","severity":"serious","_validated":true},{"effect":"Weight decreased","drugRate":"reported","severity":"unknown"},{"effect":"Anastomotic healing complications","drugRate":"reported","severity":"unknown"},{"effect":"Asthenia","drugRate":"reported","severity":"unknown"},{"effect":"Blurred vision","drugRate":"reported","severity":"unknown"},{"effect":"Chest pain","drugRate":"reported","severity":"unknown"},{"effect":"Death","drugRate":"reported","severity":"unknown"}],"contraindications":["Anemia","Breastfeeding (mother)","Congenital long QT syndrome","Deep venous thrombosis","Dehydration","Diabetes mellitus","Diarrhea","Disease of liver","Hyperglycemia","Hypocalcemia","Hypokalemia","Hypomagnesemia","Pregnancy, function","Prolonged QT interval","Pulmonary thromboembolism","Thrombocytopenic disorder","Thromboembolic disorder","Vomiting"],"specialPopulations":{"Lactation":"Advise lactating women not to breastfeed during treatment with ZOLINZA and for at least week after the last dose.","Pregnancy":"ZOLINZA can cause fetal harm when administered to pregnant woman. There are insufficient data on ZOLINZA use in pregnant women to inform drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to fetus.","Geriatric use":"Clinical studies of ZOLINZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.","Paediatric use":"The safety and effectiveness of ZOLINZA in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[{"applNo":"N021991","source":"FDA Orange Book","status":"Active","expires":"Mar 18, 2028","useCode":"U-892","territory":"US","drugProduct":false,"patentNumber":"8450372","drugSubstance":false},{"applNo":"N021991","source":"FDA Orange Book","status":"Active","expires":"Mar 11, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7456219","drugSubstance":true},{"applNo":"N021991","source":"FDA Orange Book","status":"Active","expires":"May 16, 2026","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8093295","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VORINOSTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:56:00.595881+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T05:55:59.037179+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Vorinostat","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T05:56:07.371035+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:56:05.938863+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VORINOSTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:56:06.322713+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:55:57.691075+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:55:57.691112+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:55:57.691118+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histone deacetylase 2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:07.370984+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL98/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:56:07.026860+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021991","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:55:57.691122+00:00"}},"allNames":"zolinza","offLabel":[],"synonyms":["vorinostat","suberoylanilide hydroxamic acid"],"timeline":[{"date":"2006-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MERCK to Msd Sub Merck"},{"date":"2006-10-06","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck)"},{"date":"2027-03-11","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7456219 expires"}],"aiSummary":"Zolinza (Vorinostat) is a small molecule Histone Deacetylase Inhibitor (HDACi) developed by Merck and currently owned by MSD Sub Merck. It targets Histone Deacetylase 6 (HDAC6) and was FDA-approved in 2006 for the treatment of Primary Cutaneous T-cell lymphoma. Zolinza has a short half-life of 0.76 hours and moderate bioavailability of 43%. It remains a patented product with no generic manufacturers available. Key safety considerations include its potential for hepatotoxicity and thrombocytopenia.","approvals":[{"date":"2006-10-06","orphan":true,"company":"MERCK","regulator":"FDA"}],"brandName":"Zolinza","ecosystem":[{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"target":"Histone deacetylase 6","novelty":"Follow-on","targets":[{"gene":"HDAC6","source":"DrugCentral","target":"Histone deacetylase 6","protein":"Histone deacetylase 6"},{"gene":"HDAC1","source":"DrugCentral","target":"Histone deacetylase 1","protein":"Histone deacetylase 1"},{"gene":"HDAC2","source":"DrugCentral","target":"Histone deacetylase 2","protein":"Histone deacetylase 2"},{"gene":"HDAC3","source":"DrugCentral","target":"Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)","protein":"Histone deacetylase 3"},{"gene":"NCOR2","source":"DrugCentral","target":"Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)","protein":"Nuclear receptor corepressor 2"},{"gene":"BRD4","source":"DrugCentral","target":"Bromodomain-containing protein 4","protein":"Bromodomain-containing protein 4"},{"gene":"HDAC10","source":"DrugCentral","target":"Histone deacetylase","protein":"Histone deacetylase 10"},{"gene":"HDAC11","source":"DrugCentral","target":"Histone deacetylase","protein":"Histone deacetylase 11"},{"gene":"HDAC4","source":"DrugCentral","target":"Histone deacetylase","protein":"Histone deacetylase 4"},{"gene":"HDAC5","source":"DrugCentral","target":"Histone deacetylase","protein":"Histone deacetylase 5"}],"moaClass":"Histone Deacetylase Inhibitors","modality":"Small Molecule","drugClass":"Histone Deacetylase Inhibitor [EPC]","explanation":"Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with condensed chromatin structure and repression of gene transcription. Inhibition of HDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in an open chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat","oneSentence":"Zolinza works by blocking the action of histone deacetylase 6, an enzyme that removes acetyl groups from histones, leading to changes in gene expression.","technicalDetail":"Zolinza (Vorinostat) is a pan-HDAC inhibitor that selectively targets HDAC6, leading to the accumulation of acetylated tubulin and the disruption of microtubule dynamics, ultimately resulting in cell cycle arrest and apoptosis in cancer cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Vorinostat","title":"Vorinostat","extract":"Vorinostat (rINN), also known as suberoylanilide hydroxamic acid, is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities."},"commercial":{"launchDate":"2006","_launchSource":"DrugCentral (FDA 2006-10-06, MERCK)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4124","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VORINOSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VORINOSTAT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Vorinostat","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:09:54.373580","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:12.698891+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"romidepsin","drugSlug":"romidepsin","fdaApproval":"2009-11-05","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"panobinostat","drugSlug":"panobinostat","fdaApproval":"2015-02-23","patentExpiry":"Jun 13, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"belinostat","drugSlug":"belinostat","fdaApproval":"2014-07-03","patentExpiry":"Oct 27, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"vorinostat","indications":{"approved":[{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA","eligibility":"patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies"}],"offLabel":[],"pipeline":[]},"currentOwner":"Msd Sub Merck","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"romidepsin","brandName":"romidepsin","genericName":"romidepsin","approvalYear":"2009","relationship":"same-class"},{"drugId":"panobinostat","brandName":"panobinostat","genericName":"panobinostat","approvalYear":"2015","relationship":"same-class"},{"drugId":"belinostat","brandName":"belinostat","genericName":"belinostat","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00091559","phase":"PHASE2","title":"Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"startDate":"2005-02-03","conditions":["Cutaneous T-cell Lymphoma","Sezary Syndrome","Mycosis Fungoides"],"enrollment":74,"completionDate":"2006-03-13"},{"nctId":"NCT01522976","phase":"PHASE2","title":"Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-01","conditions":["Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia-1","Chronic Myelomonocytic Leukemia-2","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Excess Blasts-1","Myelodysplastic Syndrome/Acute Myeloid Leukemia"],"enrollment":282,"completionDate":"2026-03-19"},{"nctId":"NCT00336063","phase":"PHASE1","title":"Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-03-03","conditions":["Adult Nasal Type Extranodal NK/T-Cell Lymphoma","Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Recurrent Nasopharyngeal Undifferentiated Carcinoma","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7"],"enrollment":18,"completionDate":"2026-03-19"},{"nctId":"NCT01587352","phase":"PHASE2","title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":["Metastatic Uveal Melanoma","Stage IV Uveal Melanoma AJCC v7"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Recurrent Adult Brain Neoplasm"],"enrollment":83,"completionDate":"2026-04-24"},{"nctId":"NCT00392353","phase":"PHASE1,PHASE2","title":"Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-22","conditions":["Acute Erythroid Leukemia","Acute Megakaryoblastic Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Ring Sideroblasts","Recurrent Adult Acute Myeloid Leukemia","Refractory Anemia"],"enrollment":135,"completionDate":"2026-12-31"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT03742245","phase":"PHASE1","title":"Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-06-11","conditions":["Breast Cancer Metastatic","Breast Cancer"],"enrollment":28,"completionDate":"2026-12-01"},{"nctId":"NCT00616967","phase":"PHASE2","title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-05","conditions":["Breast Cancer"],"enrollment":68,"completionDate":"2027-02"},{"nctId":"NCT06995521","phase":"PHASE2","title":"Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population","status":"NOT_YET_RECRUITING","sponsor":"Sung Won Choi","startDate":"2026-03","conditions":["GVHD"],"enrollment":55,"completionDate":"2028-06"},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":["Neuroblastoma"],"enrollment":500,"completionDate":"2035-09"},{"nctId":"NCT06693284","phase":"EARLY_PHASE1","title":"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-11-20","conditions":["Primary Malignant Peripheral Nerve Sheath Tumors"],"enrollment":8,"completionDate":"2027-01-01"},{"nctId":"NCT00875056","phase":"PHASE2","title":"Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":["Lymphoma"],"enrollment":56,"completionDate":"2019-02-08"},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":15,"completionDate":"2027-12-30"},{"nctId":"NCT03842696","phase":"PHASE1,PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":["Hematologic Diseases","Acute Leukemia in Remission","Chronic Myelogenous Leukemia - Chronic Phase","Chronic Myelogenous Leukemia, Accelerated Phase","Chronic Myelogenous Leukemia, Blastic Phase","Myelodysplastic Syndromes","Mantle Cell Lymphoma","Follicular Lymphoma","Diffuse Large B Cell Lymphoma","Non Hodgkin Lymphoma","Graft Vs Host Disease","Graft-versus-host-disease"],"enrollment":43,"completionDate":"2026-04-01"},{"nctId":"NCT01087554","phase":"PHASE1","title":"Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-03","conditions":["Advanced Cancer"],"enrollment":249,"completionDate":"2026-08-18"},{"nctId":"NCT05848687","phase":"PHASE1,PHASE2","title":"TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II","status":"RECRUITING","sponsor":"Tanja Andrea Gruber","startDate":"2023-11-03","conditions":["Lymphoblastic Leukemia"],"enrollment":90,"completionDate":"2033-12"},{"nctId":"NCT05317403","phase":"PHASE1","title":"Venetoclax to Augment Epigenetic Modification and Chemotherapy","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-03-31","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"enrollment":40,"completionDate":"2027-01"},{"nctId":"NCT03167437","phase":"PHASE1,PHASE2","title":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-10-30","conditions":["Crohn's Disease"],"enrollment":35,"completionDate":"2026-06-30"},{"nctId":"NCT02638090","phase":"PHASE1,PHASE2","title":"Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-22","conditions":["Lung Cancer","Non-small Cell Lung Cancer"],"enrollment":120,"completionDate":"2026-07"},{"nctId":"NCT07217379","phase":"PHASE1","title":"The DART DELIVER-02 Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-10-02","conditions":["HIV (Human Immunodeficiency Virus)"],"enrollment":24,"completionDate":"2027-02"},{"nctId":"NCT02553460","phase":"PHASE1,PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2031-10"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":["Neuroblastoma"],"enrollment":118,"completionDate":"2031-07-31"},{"nctId":"NCT03259503","phase":"PHASE1","title":"Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2025-11-05"},{"nctId":"NCT01281176","phase":"PHASE1","title":"High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-09","conditions":["Adult Solid Neoplasm"],"enrollment":20,"completionDate":"2026-04-17"},{"nctId":"NCT05756660","phase":"EARLY_PHASE1","title":"Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy","status":"SUSPENDED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-03-01","conditions":["Ototoxicity, Drug-Induced"],"enrollment":33,"completionDate":"2027-01"},{"nctId":"NCT03263936","phase":"PHASE1","title":"Epigenetic Reprogramming in Relapse/Refractory AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2017-07-11","conditions":["Acute Myelogenous Leukemia"],"enrollment":37,"completionDate":"2022-02-10"},{"nctId":"NCT03426891","phase":"PHASE1","title":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-03-16","conditions":["Glioblastoma","Brain Tumor","GBM"],"enrollment":21,"completionDate":"2023-06-28"},{"nctId":"NCT00972478","phase":"PHASE1,PHASE2","title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-15","conditions":["Ann Arbor Stage II Non-Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma"],"enrollment":83,"completionDate":"2026-03-06"},{"nctId":"NCT03150329","phase":"PHASE1","title":"Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-07-18","conditions":["Grade 3b Follicular Lymphoma","Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL","Recurrent Classic Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL","Refractory Classic Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Transformed Non-Hodgkin Lymphoma"],"enrollment":52,"completionDate":"2026-07-01"},{"nctId":"NCT07150013","phase":"PHASE1","title":"Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Unravel Biosciences, Inc.","startDate":"2025-10-15","conditions":["Rett Syndrome"],"enrollment":15,"completionDate":"2026-10-15"},{"nctId":"NCT07150026","phase":"PHASE1","title":"An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Unravel Biosciences, Inc.","startDate":"2025-10-15","conditions":["Pitt Hopkins Syndrome"],"enrollment":5,"completionDate":"2026-10-15"},{"nctId":"NCT03843528","phase":"PHASE1","title":"Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2019-05-01","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Mixed Phenotype Acute Leukemia","Juvenile Myelomonocytic Leukemia"],"enrollment":15,"completionDate":"2026-10-30"},{"nctId":"NCT02836548","phase":"PHASE1,PHASE2","title":"HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2016-06","conditions":["Melanoma","Skin Neoplasms"],"enrollment":33,"completionDate":"2023-11"},{"nctId":"NCT00838929","phase":"PHASE1","title":"Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-03","conditions":["Brain Metastases"],"enrollment":17,"completionDate":"2015-03"},{"nctId":"NCT03332667","phase":"PHASE1","title":"MIBG With Dinutuximab +/- Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2018-09-12","conditions":["Neuroblastoma"],"enrollment":45,"completionDate":"2024-02-23"},{"nctId":"NCT04339751","phase":"PHASE2","title":"Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease","status":"WITHDRAWN","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2025-04-11","conditions":["Cushing's Disease"],"enrollment":0,"completionDate":"2025-04-11"},{"nctId":"NCT05608369","phase":"PHASE2","title":"Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-06-01","conditions":["HPV-Related Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Oropharynx","Squamous Cell Carcinoma of the Hypopharynx"],"enrollment":0,"completionDate":"2026-02-01"},{"nctId":"NCT02420613","phase":"PHASE1","title":"Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-10-05","conditions":["Diffuse Intrinsic Pontine Glioma"],"enrollment":18,"completionDate":"2025-03-28"},{"nctId":"NCT00503971","phase":"PHASE1,PHASE2","title":"Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.","status":"TERMINATED","sponsor":"Spanish Lung Cancer Group","startDate":"2008-05","conditions":["Non-small Cell Lung Cancer"],"enrollment":33,"completionDate":"2011-12"},{"nctId":"NCT04357873","phase":"PHASE2","title":"Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2020-10-28","conditions":["Squamous Cell Lung Cancer","Vulvar Cancer","Penile Cancer","Cervix Cancer","Head and Neck Squamous Cell Carcinoma","Anal Cancer"],"enrollment":112,"completionDate":"2024-11-26"},{"nctId":"NCT02538510","phase":"PHASE1,PHASE2","title":"Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10-08","conditions":["Head and Neck Squamous Cell Carcinoma","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharynx Carcinoma","Recurrent Salivary Gland Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage III Major Salivary Gland Carcinoma","Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage III Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Major Salivary Gland Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2023-09-15"},{"nctId":"NCT02619253","phase":"PHASE1","title":"Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma","status":"COMPLETED","sponsor":"Nabil Adra","startDate":"2016-02-23","conditions":["Renal Cell Carcinoma","Urinary Bladder Neoplasms"],"enrollment":52,"completionDate":"2023-03-28"},{"nctId":"NCT01413750","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-08","conditions":["Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7","Stage IV Lung Non-Small Cell Cancer AJCC v7"],"enrollment":23,"completionDate":"2013-04-14"},{"nctId":"NCT03263533","phase":"EARLY_PHASE1","title":"HDAC Inhibitor Augmentation to Clozapine","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2017-04","conditions":["Schizophrenia"],"enrollment":0,"completionDate":"2019-02"},{"nctId":"NCT00555399","phase":"PHASE1,PHASE2","title":"Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-28","conditions":["Glioblastoma Multiforme","Anaplastic Glioma"],"enrollment":55,"completionDate":"2020-01-24"},{"nctId":"NCT03382834","phase":"PHASE2","title":"Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-26","conditions":["HIV Infections"],"enrollment":31,"completionDate":"2023-07-27"},{"nctId":"NCT01728805","phase":"PHASE3","title":"Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2012-11","conditions":["Cutaneous T-Cell Lymphoma"],"enrollment":372,"completionDate":"2021-02-17"},{"nctId":"NCT03056495","phase":"PHASE1","title":"Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease","status":"TERMINATED","sponsor":"German Center for Neurodegenerative Diseases (DZNE)","startDate":"2017-09-28","conditions":["Alzheimer Disease"],"enrollment":9,"completionDate":"2024-03-04"},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Anatomic Stage IV Breast Cancer AJCC v8","Anemia","Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Castration-Resistant Prostate Carcinoma","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Pancreatic Adenocarcinoma","Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis","Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","Primary Myelofibrosis","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent Myelodysplastic Syndrome","Recurrent Myelodysplastic/Myeloproliferative Neoplasm","Recurrent Myeloproliferative Neoplasm","Recurrent Non-Hodgkin Lymphoma","Recurrent Plasma Cell Myeloma","Recurrent Small Lymphocytic Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Chronic Myelomonocytic Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Myelodysplastic Syndrome","Refractory Myelodysplastic/Myeloproliferative Neoplasm","Refractory Non-Hodgkin Lymphoma","Refractory Plasma Cell Myeloma","Refractory Primary Myelofibrosis","Refractory Small Lymphocytic Lymphoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma"],"enrollment":2,"completionDate":"2020-12-10"},{"nctId":"NCT05700630","phase":"PHASE1","title":"Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-07-15","conditions":["HIV-1-infection","ART","Cd4+ Lymphocyte Deficiency","Lymphoid Tissue; Infection","Interleukin"],"enrollment":0,"completionDate":"2024-08-21"},{"nctId":"NCT01236560","phase":"PHASE2,PHASE3","title":"Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-26","conditions":["Brain Stem Glioma","Cerebral Astrocytoma","Childhood Cerebellar Anaplastic Astrocytoma","Childhood Cerebral Anaplastic Astrocytoma","Childhood Spinal Cord Neoplasm"],"enrollment":101,"completionDate":"2023-12-31"},{"nctId":"NCT03198559","phase":"PHASE1,PHASE2","title":"Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART","status":"TERMINATED","sponsor":"University of Melbourne","startDate":"2017-08-08","conditions":["HIV Infections"],"enrollment":5,"completionDate":"2019-04-09"},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":["Recurrent Aggressive Non-Hodgkin Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma"],"enrollment":0,"completionDate":"2021-10-29"},{"nctId":"NCT02316340","phase":"PHASE2","title":"Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-02-11","conditions":["Colorectal Cancer"],"enrollment":42,"completionDate":"2018-04-16"},{"nctId":"NCT01193842","phase":"PHASE1,PHASE2","title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-06","conditions":["AIDS-Related Plasmablastic Lymphoma","AIDS-Related Primary Effusion Lymphoma","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","Ann Arbor Stage I Grade 3 Follicular Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Grade 3 Follicular Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Grade 3 Follicular Lymphoma","HIV Infection","Plasmablastic Lymphoma","Primary Effusion Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Grade 3 Follicular Lymphoma"],"enrollment":107,"completionDate":"2022-05-19"},{"nctId":"NCT04308330","phase":"PHASE1","title":"Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies","status":"UNKNOWN","sponsor":"New York Medical College","startDate":"2017-03-17","conditions":["Ewing Sarcoma","Rhabdomyosarcoma","Wilms Tumor","Neuroblastoma","Hepatoblastoma","Germ Cell Tumor"],"enrollment":30,"completionDate":"2024-12-31"},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":["HIV"],"enrollment":60,"completionDate":"2023-03-31"},{"nctId":"NCT04190056","phase":"PHASE2","title":"Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2021-03-11","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":1,"completionDate":"2023-06-15"},{"nctId":"NCT01838187","phase":"","title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","status":"NO_LONGER_AVAILABLE","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"","conditions":["Neuroblastoma","Pheochromocytoma","Paraganglioma"],"enrollment":0,"completionDate":""},{"nctId":"NCT02475915","phase":"PHASE1,PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":["Acute HIV Infection"],"enrollment":15,"completionDate":"2016-03"},{"nctId":"NCT03212989","phase":"PHASE1","title":"Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-06-27","conditions":["HIV-1 Infection"],"enrollment":17,"completionDate":"2022-07-05"},{"nctId":"NCT00455351","phase":"PHASE1","title":"Vorinostat and Palliative Radiotherapy","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2007-02","conditions":["Pelvic Cancer","Radiotherapy"],"enrollment":15,"completionDate":"2009-08"},{"nctId":"NCT01019850","phase":"PHASE1","title":"N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2010-03","conditions":["Neuroblastoma"],"enrollment":27,"completionDate":"2015-02"},{"nctId":"NCT03561259","phase":"PHASE2","title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","status":"UNKNOWN","sponsor":"Jubilant DraxImage Inc.","startDate":"2019-10-21","conditions":["Neuroblastoma","Neuroectodermal Tumors","Neoplasms"],"enrollment":60,"completionDate":"2025-04"},{"nctId":"NCT01023737","phase":"PHASE1","title":"Hydroxychloroquine + Vorinostat in Advanced Solid Tumors","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-11","conditions":["Malignant Solid Tumour"],"enrollment":72,"completionDate":"2023-01-08"},{"nctId":"NCT01174199","phase":"PHASE1","title":"Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-02","conditions":["Prostate Cancer","Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer"],"enrollment":13,"completionDate":"2016-08"},{"nctId":"NCT00419367","phase":"","title":"Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)","status":"NO_LONGER_AVAILABLE","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":["Lymphoma, T-Cell, Cutaneous"],"enrollment":0,"completionDate":""},{"nctId":"NCT01879085","phase":"PHASE1,PHASE2","title":"Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma","status":"COMPLETED","sponsor":"Melissa Burgess, MD","startDate":"2013-09-24","conditions":["Sarcoma"],"enrollment":37,"completionDate":"2021-04-15"},{"nctId":"NCT02349867","phase":"PHASE1","title":"Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-01-29","conditions":["Pancreatic Adenocarcinoma","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Recurrent Pancreatic Carcinoma"],"enrollment":23,"completionDate":"2022-05-13"},{"nctId":"NCT00127127","phase":"PHASE1","title":"A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06-10","conditions":["Tumors"],"enrollment":18,"completionDate":"2009-08-21"},{"nctId":"NCT00731731","phase":"PHASE1,PHASE2","title":"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-10","conditions":["Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma"],"enrollment":125,"completionDate":"2019-11-01"},{"nctId":"NCT02042989","phase":"PHASE1","title":"MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-06-27","conditions":["Advanced Cancers"],"enrollment":68,"completionDate":"2020-01-22"},{"nctId":"NCT02035137","phase":"PHASE2","title":"131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-07","conditions":["Neuroblastoma"],"enrollment":114,"completionDate":"2021-02-26"},{"nctId":"NCT03713320","phase":"PHASE2","title":"SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides","status":"TERMINATED","sponsor":"miRagen Therapeutics, Inc.","startDate":"2019-04-02","conditions":["Cutaneous T-Cell Lymphoma/Mycosis Fungoides"],"enrollment":37,"completionDate":"2020-12-01"},{"nctId":"NCT00785798","phase":"PHASE1,PHASE2","title":"Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas","status":"TERMINATED","sponsor":"Yale University","startDate":"2009-01","conditions":["Relapsed Lymphomas","Refractory Lymphomas"],"enrollment":17,"completionDate":"2011-09"},{"nctId":"NCT04324099","phase":"","title":"Investigating the Specificity of Neural Correlates for Emotion Processing Deficits in Conduct Disorder and Autism Spectrum Disorders","status":"UNKNOWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-07-16","conditions":["Autism-Spectrum Disorder","Conduct Disorder"],"enrollment":120,"completionDate":"2023-06"},{"nctId":"NCT01502085","phase":"PHASE1,PHASE2","title":"Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2011-12","conditions":["Multiple Myeloma"],"enrollment":25,"completionDate":"2016-05"},{"nctId":"NCT00867178","phase":"PHASE1","title":"Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-25","conditions":["Medulloblastoma","Pineoblastoma","Supratentorial Embryonal Tumor, Not Otherwise Specified"],"enrollment":33,"completionDate":"2021-12-22"},{"nctId":"NCT02083250","phase":"PHASE1","title":"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-03-06","conditions":["Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia in Remission","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia"],"enrollment":70,"completionDate":"2021-11-12"},{"nctId":"NCT03803605","phase":"PHASE1","title":"Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-02-12","conditions":["HIV-1 Infection"],"enrollment":15,"completionDate":"2021-01-28"},{"nctId":"NCT01294670","phase":"PHASE1,PHASE2","title":"Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-02-09","conditions":["Solid Tumors","Relapsed/Refractory Sarcomas"],"enrollment":27,"completionDate":"2020-12-08"},{"nctId":"NCT01038388","phase":"PHASE1","title":"A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-01-15","conditions":["Multiple Myeloma"],"enrollment":30,"completionDate":"2021-08-05"},{"nctId":"NCT01189266","phase":"PHASE1,PHASE2","title":"Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-09","conditions":["Anaplastic Astrocytoma","Anaplastic Oligoastrocytoma","Diffuse Intrinsic Pontine Glioma","Gliosarcoma"],"enrollment":79,"completionDate":"2021-09-30"},{"nctId":"NCT01110876","phase":"PHASE1,PHASE2","title":"Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06","conditions":["Brain Cancer","Glioblastoma Multiforme"],"enrollment":21,"completionDate":"2014-07"},{"nctId":"NCT01720875","phase":"PHASE2","title":"Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2013-08-09","conditions":["Multiple Myeloma"],"enrollment":16,"completionDate":"2018-08-29"},{"nctId":"NCT01617226","phase":"PHASE2","title":"Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2012-09","conditions":["Leukemia, Myeloid, Acute"],"enrollment":260,"completionDate":"2020-12"},{"nctId":"NCT00773747","phase":"PHASE3","title":"Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-01","conditions":["Multiple Myeloma"],"enrollment":637,"completionDate":"2015-06-30"},{"nctId":"NCT00858234","phase":"PHASE1","title":"Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-13","conditions":["Multiple Myeloma"],"enrollment":9,"completionDate":"2012-04-19"},{"nctId":"NCT03050450","phase":"PHASE1","title":"Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors","status":"TERMINATED","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2016-08-10","conditions":["Central Nervous System Tumors"],"enrollment":8,"completionDate":"2018-12-19"},{"nctId":"NCT00773838","phase":"PHASE2","title":"Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-01","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":143,"completionDate":"2012-04-09"},{"nctId":"NCT01266057","phase":"PHASE1","title":"Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04-28","conditions":["Advanced Cancers"],"enrollment":143,"completionDate":"2021-02-11"},{"nctId":"NCT00324740","phase":"PHASE1,PHASE2","title":"Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-03","conditions":["Recurrent Renal Cell Cancer","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer"],"enrollment":14,"completionDate":"2014-05"},{"nctId":"NCT01169532","phase":"PHASE1","title":"Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2010-10","conditions":["Lymphoma","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":16,"completionDate":"2014-03"},{"nctId":"NCT00691210","phase":"PHASE1","title":"Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies","status":"COMPLETED","sponsor":"Columbia University","startDate":"2008-06","conditions":["Hodgkin's Disease","Non-Hodgkin's Lymphoma"],"enrollment":40,"completionDate":"2015-03"},{"nctId":"NCT00821951","phase":"PHASE1","title":"Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-05","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":17,"completionDate":"2012-07"},{"nctId":"NCT00642954","phase":"PHASE1","title":"Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-13","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":31,"completionDate":"2013-08-20"},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":["Urothelial Carcinoma","Bladder Cancer","Urinary Bladder Neoplasms"],"enrollment":8,"completionDate":"2019-10-23"},{"nctId":"NCT01483690","phase":"PHASE1,PHASE2","title":"A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2011-12","conditions":["Acute Lymphoblastic Leukemia","Precursor B-Cell Lymphoblastic Leukemia","Precursor T-Cell Lymphoblastic Leukemia"],"enrollment":23,"completionDate":"2015-07-31"},{"nctId":"NCT00128102","phase":"PHASE3","title":"Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06-30","conditions":["Mesothelioma","Lung Cancer"],"enrollment":661,"completionDate":"2011-11-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT00091559"],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"ZOLINZA"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179580","MMSL":"22259","NDDF":"011760","UNII":"58IFB293JI","VUID":"4025777","CHEBI":"CHEBI:45716","VANDF":"4025777","INN_ID":"8661","RXNORM":"194337","UMLSCUI":"C0672708","chemblId":"CHEMBL98","ChEMBL_ID":"CHEMBL98","KEGG_DRUG":"D06320","DRUGBANK_ID":"DB02546","PDB_CHEM_ID":"SHH","PUBCHEM_CID":"5311","SNOMEDCT_US":"422505001","IUPHAR_LIGAND_ID":"6852","MESH_DESCRIPTOR_UI":"D000077337"},"formularyStatus":[],"originalProduct":{"form":"CAPSULE","route":"ORAL","company":"Merck Sharp & Dohme Corp.","brandName":"ZOLINZA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2006-","companyName":"Merck","relationship":"Original Developer"},{"period":"present","companyName":"Msd Sub Merck","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.76 hours","clearance":"28.0 mL/min/kg","bioavailability":"43%","fractionUnbound":"0.29%","volumeOfDistribution":"0.5 L/kg"},"publicationCount":2108,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XH01","allCodes":["L01XH01"]},"biosimilarFilings":[],"originalDeveloper":"Merck","recentPublications":[{"date":"2026 Mar 25","pmid":"41903478","title":"Design, synthesis, and in silico study of VEGFR-2 and HDAC dual acting quinazoline based molecules for anticancer evaluation.","journal":"Bioorganic chemistry"},{"date":"2026 Mar 22","pmid":"41895167","title":"In silico discovery of selective TPX2 and BUB1B inhibitors as novel antimitotic agents in breast cancer therapy.","journal":"Computational biology and chemistry"},{"date":"2026 Mar 26","pmid":"41885112","title":"Latent HIV Reservoirs in the Central Nervous System: Mechanisms, Barriers, and Therapeutic Approaches.","journal":"ACS infectious diseases"},{"date":"2026 Mar 19","pmid":"41880788","title":"Towards the discovery of potent epigenetic modulators: Design, synthesis, biological evaluation, and SAR investigation of novel indole-based derivatives targeting HDAC1 and HDAC6.","journal":"Bioorganic chemistry"},{"date":"2026","pmid":"41878673","title":"Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment.","journal":"Drug design, development and therapy"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Msd Sub Merck","companyId":"merck","modality":"Small molecule","firstApprovalDate":"2006","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-10-06T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":18,"withResults":4},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:56:12.698891+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}